Quantcast

Latest Alkaloids Stories

2010-09-30 11:00:00

BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to surveyed European oncologists, Johnson & Johnson's abiraterone will capture greater patient share than Dendreon's Provenge, AstraZeneca's zibotentan or Bristol-Myers Squibb's ipilimumab in asymptomatic or minimally symptomatic, metastatic castrate-resistant prostate cancer (MCRPC). According to the new...

2010-09-22 05:00:00

Randomized Phase 2 Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Chi K.N., et al. JCO Sep 20, 2010: 4247-4254 BOTHELL, WA and VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today publication of results from a randomized Phase 2 trial in the Journal of Clinical Oncology. The trial results showed a survival benefit with the investigational agent OGX-011/TV1011...

2010-09-02 06:30:00

TORONTO, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer...

2010-08-24 13:57:19

When nicotine binds to the nicotinic acetylcholine receptor (nAchR), it is known to promote smoking addiction and may also directly promote the development of breast cancer, according to a study published online August 23 in The Journal of the National Cancer Institute. While smoking is a well-known risk factor for a broad range of cancer types, non-nicotine components of tobacco have generally been thought to be the carcinogens, so little is known about how nicotine acts on cells to promote...

2010-08-17 17:00:06

Inhibiting a cell division-regulating protein can improve response to taxane chemotherapy For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy. Findings were reported by researchers from The University of Texas MD Anderson Cancer Center in the August issue of Cancer Cell. The study adds to growing evidence that combination therapies targeting different phases of the cell...

2010-08-12 15:04:07

How toxic, blue-green algae out-compete other organisms through a form of selfish "enslavement" -- and by so doing proliferate dangerously in freshwater bodies -- has been described by a researcher at the Hebrew University of Jerusalem. In general, the increasing occurrence of toxic cyanobacterial (blue-green algae) blooms in freshwater bodies is a matter of growing international concern due to their detrimental impact on drinking water quality and, in extreme cases, causing death to humans,...

2010-08-05 07:00:00

BRIDGEWATER, N.J., Aug. 5 /PRNewswire/ -- Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages. Introduced more than 14 years ago, Taxotere is approved by the FDA for use in...

2010-07-14 12:56:00

NEW YORK, July 14 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (ANX) announces the following Webcast: LHA Life Sciences & Med Tech Day 2010 What: Presentation When: July 20, 2010 @ 10:00 AM Eastern http://www.investorcalendar.com/ Where: ClientPage.asp?ID=160318 Live over the Internet --Simply log on to the How: web at the address above. Contact:...

2010-06-21 05:00:00

BOTHELL, WA, and VANCOUVER, June 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between...

2010-06-17 14:40:00

PARIS, June 17 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for Jevtana® (cabazitaxel) Injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen. Jevtana, a microtubule inhibitor, in combination with prednisone...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.